Skip to main content
Premium Trial:

Request an Annual Quote

Rik van Heijningen

Premium
Rik van Heijningen has been named vice president of commercial operations for genomics and proteomics at Kreatech, the Dutch biotechnology company said last week.
 
According to Kreatech, van Heijningen will focus on corporate and business development for the firm’s protein, gene expression, and array comparative genomic hybridization reagent kits. 
 
Prior to joining Kreatech, van Heijningen held several sales and marketing positions with Dynal Biotech and Invitrogen in Norway, Germany, and The Netherlands.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.